What We Monitor for Cell & Gene Therapy
RMAT designation updates
Long-term follow-up (LTFU) guidance
Manufacturing (CMC) expectations
Vector production standards
Potency assay requirements
Clinical trial design (CGT-specific)
Accelerated approval pathways
Post-market safety monitoring
CGT-specific warning letters
Decisions This Intelligence Affects
Regulatory Strategy
- • RMAT designation timing
- • Accelerated pathway selection
- • BLA submission sequencing
- • International harmonization
CMC & Manufacturing
- • Vector production standards
- • Potency assay development
- • Scale-up and comparability
- • Raw material qualification
Clinical Development
- • Trial design (CGT-specific)
- • Endpoint selection
- • LTFU protocol design
- • Patient selection criteria
Commercial & Investor
- • Reimbursement positioning
- • Value demonstration strategy
- • Competitive landscape analysis
- • Pipeline communication
How CGT Teams Use This Intelligence
Navigate RMAT Requirements
Anticipate designation criteria shifts and timing expectations
Optimize CMC Strategy
Align manufacturing approach with evolving FDA expectations
Plan LTFU Requirements
Design follow-up protocols that meet current standards
Anticipate Safety Signals
Monitor CGT-specific post-market requirements
Strengthen BLA Submissions
Build applications aligned with current CGT precedent
Brief Investors Confidently
Communicate regulatory pathway with precision